Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01011933 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenocarcinoma
Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Recurrent Uterine Corpus Carcinoma

Interventions

OTHER: Diagnostic Laboratory Biomarker Analysis
DRUG: Selumetinib

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]